Naim Alkhouri, MD

Dr. Naim Alkhouri is board-certified in Internal Medicine and Obesity Medicine

Naim Alkhouri, MD, holds multiple prestigious roles in the gastroenterology and hepatology field. He serves as the Director of the Steatotic Liver Program at Northshore Gastroenterology and holds the position of Director of Research at the Clinical Research Institute of Ohio (CRIOH). Additionally, Dr. Alkhouri is the Chief Medical Officer, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Before taking on these roles, he served as the Director of the Metabolic Health Center at the Texas Liver Institute. Additionally, Dr. Alkhouri previously held the dual role of Assistant Professor in both Medicine and Pediatrics at the University of Texas (UT) Health, located in San Antonio, TX.

Dr. Alkhouri concluded his Gastroenterology and Transplant Hepatology training at the esteemed Cleveland Clinic in Cleveland, OH. During this time, he assumed the role of Assistant Professor of Medicine and was entrusted with directing the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute. Recognized as a leading authority in NASH therapeutics, Dr. Alkhouri serves as an advisor and consultant to numerous pharmaceutical and biomarker development companies. He holds the position of Principal Investigator in several multicenter, global NASH trials and is an active member of the AASLD NASH Special Interest Group (NASH SIG).

Dr. Alkhouri showcases an extensive publication record exceeding 200 contributions, coupled with presentations at prominent national and international medical gatherings. His dedication to research has earned him numerous accolades, including the American College of Gastroenterology Junior Faculty Development Award, granted for his investigation into the analysis of breath volatile organic compounds for diagnosing nonalcoholic fatty liver disease. Dr. Alkhouri's areas of expertise span nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha-1 antitrypsin deficiency, and liver transplantation.